Gb0139 galecto

Author: nfwr

August undefined, 2024

Webcenters globally, investigating the safety and efficacy of Galecto s lead compound, GB0139, in patients with IPF. Initial unblinded data readout is anticipated in 2024. The DSMB informed the company, based on unblinded safety and efficacy data, that there was an imbalance in the serious adverse experiences WebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary ...

GB0139 on Idiopathic Pulmonary Fibrosis (IPF) - ICH GCP

WebFeb 6, 2024 · Prior use of GB0139 (also called TD139) or previously randomized in GALACTIC-1. ... Galecto Biotech AB: ClinicalTrials.gov Identifier: NCT03832946 Other … WebApr 26, 2024 · The study is designed to investigate the safety and efficacy of Galecto’s most advanced compound, GB0139, in 141 patients with IPF. Patients in GALACTIC-1 … sharlene hilton mcclendon lpc

Orbimed Advisors Llc Sells 51,228 Shares of Galecto, Inc.

WebMay 22, 2024 · On May 6, Galecto announced that it had recruited more than 150 patients to date for its Phase IIb GALACTIC-1 study of GB0139 (formerly TD139) for idiopathic pulmonary fibrosis (IPF). GP0139 is an inhaled galectin-3 inhibitor. The company stated that its ability to recruit, especially in areas that have been most affected by Covid-19, namely ... WebFeb 1, 2024 · Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary ... WebThe anti-fibrotic effect of GB0139, a small molecule galectin-3 inhibitor, in precision cut lung slices from IPF tissue (ICLAF 2024) - "The reduction in Gal-3 levels was associated with a reduction in markers of fibrosis comparable to that observed with pirfenidone and nintedanib. In IPF PCLuS, GB0139 demonstrates Gal-3 target engagement that ... population of hartville ohio

Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 …

Galecto Announces Outcome of Data Safety Monitoring Board …

WebIt natively comes with conventional UT, TOFD and all beam-forming phased array UT techniques for single-beam and multi-group inspection and its 3-encoded axis … WebDec 31, 2024 · BOSTON , March 02, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present and be available for 1x1. 01 Feb '23. sharlene hieronimusWebGalecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team … sharlene hesse-biber

"WebApr 26, 2024 · GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2024 BOSTON, April 26, 2024 (GLOBE NEWSWIRE ... " - Gb0139 galecto

Gb0139 galecto

WebGalecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical GB0139 significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulation; Data demonstrate potential of GB0139 in patients with viral-induced acute lung injury; Currently Galecto will prioritize resources for its four phase 2 trials in fibrosis and cancer

Did you know?

WebDrug DetailsGB0139 (formerly TD139) is a galectin-3 inhibitor administered by dry powder inhalation.Study PurposeThis is a randomized, double-blind, placebo-controlled phase … WebDec 21, 2024 · Rationale High galectin-3 levels predict poor outcomes in patients with COVID-19. Galectin-3 activates monocytes and macrophages which are directly …

WebJan 1, 2024 · TD139 (GB0139) Galecto, Inc. (Copenhagen, Denmark) Dry powder inhaler QD • Phase Ia/Ib - safety, tolerability, PK and biomarkers in healthy volunteers and patients with IPF completed (NCT02257177). • Phase IIb - efficacy and safety study (GALACTIC-1, NCT03832946) in IPF patients. GB1211: Galecto, Inc. (Copenhagen, Denmark) Oral … WebFeb 2, 2024 · Beltone is a leading global hearing aid brand with a strong retail presence in North America through 1,500 hearing care centers. Founded in 1940 and based in …

WebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis; (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 ... WebDec 21, 2024 · 10 mg GB0139 twice daily for 48 hours, then once daily for 14 days (n=20). Results: Patients aged 27–87 years were enrolled from July 2024; the final patient completed the 90-day follow-up in April 2024. GB0139+SOC was well tolerated with no treatment-related serious adverse events reported. Incidences of adverse events were

WebJun 22, 2024 · Galecto has multiple clinical programs in fibrosis and cancer focused on galectin-3 and LOXL2, including an inhaled galectin-3 modulator (GB0139) currently in a …

WebAug 8, 2024 · Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological … sharlene henry realtyWebMar 15, 2024 · GALACTIC-1 is a 52-week randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b study being conducted across more than 100 centers globally, investigating the safety and ... sharlene hobermanWebGalecto builds on more than 10 years of research centering on the role of galectin-3 and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. In addition to the lead product candidate, GB0139, the company’s ... sharlene h mcclendonWebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the … sharlene hodgeWebNov 30, 2024 · Galecto is now investigating GB0139 (formerly TD139) in the Phase 2b/3 GALACTIC-1 clinical trial in IPF. The trial is a pivotal size, randomized, double-blind, … sharlene hill sharlene hock dds lincoln neWebAug 27, 2024 · GB0139 (formerly TD139) is an inhaled small molecule inhibitor of galectin-3, a protein known to play a central role in fibrosis in several organs. The company is investigating GB0139 in its Phase 2b GALACTIC-1 clinical trial in IPF. ... Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and … population of hartwell ga